Introduction
Despite advances in diagnosis and treatment, breast cancer remains a leading cause of death from cancer in women worldwide. Some forms of breast cancer, such as that characterized by ERBB2 overexpression, are particularly aggressive and even targeted therapies fail to achieve long-lasting cures. Recent evidence suggests that tumor recurrence may be due to therapy-resistant tumor-initiating cell (TIC) (Kakarala and Wicha, 2008) . However, identifying novel therapies targeting breast TIC has been impeded by the small sample size of most human breast tumors, the very low frequency of TIC in these tumors and the inability to sufficiently purify TIC for their specific study. Moreover, means to reproducibly establish and propagate TIC-enriched human breast tumor cell populations in vitro have not been developed. In consequence, we explored the use of a mouse model of breast cancer (Guy et al., 1992) , which suffers from none of these limitations, to identify molecular targets required for TIC activity.
Although mouse models do not completely reproduce the diversity of human breast cancer subtypes, morphological analyses, biomarker studies and transcript profiling suggest that they provide approximate replicas of their human counterparts (Cardiff et al., 2001; Lin et al., 2003; Borowsky et al., 2004; Herschkowitz et al., 2007) . For example, mouse mammary tumors occurring in the ERBB2 model are morphologically similar to certain human breast tumor histological subtypes (Rosner et al., 2002) and share a gene expression signature characteristic of the luminal B molecular subclass of human breast tumors (Herschkowitz et al., 2007) .
We recently found that mammary tumors arising in several transgenic mouse models, including the ERBB2 model, constitute a high fraction (1/5-1/2; 95% confidence interval) of TIC as determined by limiting dilution cell transplantation (Kurpios et al., manuscript submitted) . Moreover, cells from these tumors readily form non-adherent tumorspheres in vitro (Youn et al., 2006) that similarly comprise a high TIC fraction (Kurpios et al., manuscript submitted) . The availability of TIC-rich tumor cell populations afforded the opportunity to identify compounds that target these cells. We report that MRK-003, an orally active inhibitor of g-secretase, a protease complex required for Notch signaling (Kopan and Ilagan, 2009) , eliminated TIC in vitro and in vivo by multiple mechanisms.
Results

Differential expression of Notch pathway-related genes
To investigate a potential role for the Notch pathway in breast TIC, we performed quantitative reverse transcriptase (RT)-PCR with primer pairs homologous to transcripts encoding Notch pathway components and target genes. We compared transcript levels of Notchrelated genes in tumorspheres established from mammary tumors that arose in the Neu (N202) transgenic strain (Guy et al., 1992) and in mammospheres derived from the mammary glands of mice (FVB/N strain). The N202 model harbors the rat Neu proto-oncogene under the transcriptional control of the mouse mammary tumor virus promoter in the FVB/N inbred mouse strain. During tumorigenesis, deletions occur in sequences encoding the juxta-membrane region of Neu resulting in the constitutive activation of its tyrosine kinase activity (Siegel et al., 1994; Siegel and Muller, 1996) . Table 1 illustrates that several Notch-related genes were overexpressed in tumorspheres compared with mammospheres. The latter included genes encoding Notch pathway components (notch4, dtx1, dll1 and tle); target genes (hey1, runx1, krt1 and il17b); as well as lfng and mmp7, which encode proteins required for Notch glycosylation and intramembrane proteolysis (Matsuno et al., 1995; Burns et al., 2005; Sawey et al., 2007; Sawey and Crawford, 2008; Zhang et al., 2010) . These findings suggested that the Notch pathway might be more active in tumorspheres compared with mammospheres.
The effect of MRK-003 on sphere-and colony-formation by mammary epithelial cell and tumor cell populations To determine whether Notch pathway activity was required for the survival or self-renewal of tumorsphereand mammosphere-forming cells, we used MRK-003, an orally active inhibitor of g-secretase, which is required for the proteolytic processing of Notch receptors (Fan et al., 2006; Konishi et al., 2007; Lewis et al., 2007; Cullion et al., 2009; Rao et al., 2009) . We performed quantitative sphere-and colony-forming assays, which can be used to approximate the frequency of mammary epithelial stem and progenitor cells in heterogeneous cell populations (Reynolds and Weiss, 1992; Dontu et al., 2003) . Although the nature of the cells that form spheres is not known, mouse mammosphere-and tumorsphereforming cells co-fractionate with mammary epithelial stem cells (Liao et al., 2007; Cicalese et al., 2009 ) and mammary TIC (Liu et al., 2007) , respectively. Moreover, agents that affect the frequency of sphere-forming cells correspondingly alter the frequency of mammary epithelial stem cells and TIC suggesting that these cells initiate sphere-formation (Dontu et al., 2003 (Dontu et al., , 2004 Liao et al., 2007; Mani et al., 2008; Cicalese et al., 2009) .
We found that cells from the mouse mammary gland and primary tumors as well as those from established populations of mammospheres and tumorspheres formed spheres directly proportional to the number of cells seeded (Supplementary Figure 1) . Primary mammary epithelial cells formed mammospheres with a frequency of B0.1% of the total cell population (Supplementary Figure 1a) , whereas B1% of primary tumor cells formed tumorspheres (Supplementary Figure 1b) . The frequency of sphere-forming cells in established mammospheres and tumorspheres was B1% when assayed at the cell densities illustrated in Supplementary Figures 1c and d . Mammosphere-and tumorsphere-derived cells similarly formed spheres at a B1% frequency when measured by plating single cells into the wells of 96-well plates (data not shown.)
MRK-003 reduced the frequency of sphere-forming cells in a dose-dependent fashion in both primary mammary epithelial cell and tumor cell populations without any evidence of selectivity ( Figure 1a ). MRK-003 did not affect the size of any spheres that formed suggesting that it did not block the proliferation of cells during sphere formation. Similar results were obtained when cells from established mammospheres and tumorspheres were used in sphere-forming assays (Figure 1b) .
To determine whether the effect of MRK-003 was reversible, we scaled up the sphere-forming assays to include many more freshly isolated primary cells in an attempt to recover spheres that formed in the presence of the compound. Any spheres formed in the presence of the vehicle or various concentrations of MRK-003 were dissociated, and the same number of viable dispersed cells from these samples was seeded into fresh medium lacking MRK-003 to generate secondary spheres.
Cells from both vehicle-and MRK-003-treated primary mammospheres gave rise to secondary spheres with similar frequencies approximating 1% (Figure 1c) . By contrast, cells dissociated from MRK-003-treated primary tumorspheres displayed a reduced sphereforming efficiency directly proportional to the concentration of the compound that was used in the primary sphere-forming assays (Figure 1d ). Hence, MRK-003 irreversibly affected the activity of the tumorsphereforming cells, but reversibly affected that of mammosphere-forming cells. The values shown are the average fold changes between transcript levels in three independent RNA preparations of mammospheres and tumorspheres normalized to that of glyceraldehyde 3-phosphate dehydrogenase (P-value o0.05).
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To determine whether MRK-003 altered the capacity of progenitor cells to proliferate and differentiate, we performed colony-forming assays with primary mammary epithelial cell and tumor cell populations (Smalley et al., 1998; Stingl et al., 1998; Kurpios et al., 2009) . Colonies arise from a subset of single cells when they are plated at clonal densities. We found that primary mammary epithelial cells from 6-to 8-week-old virgin mice reproducibly yielded colonies at a frequency of between 5 and 10% (Supplementary Figure 2a) . By contrast, the frequency of colonies seeded by primary tumor cells varied from one tumor to another from a low of 5% to a high of 20% (Figure 2b ). The overall frequency and size of colonies formed by the primary mammary epithelial cells or primary tumor cells was unaffected by the presence MRK-003 (Figure 2a ). These findings suggested that MRK-003 did not alter the viability or proliferation of the colony-forming cells present in either primary mammary epithelial cell or tumor cell populations under the conditions used for these assays.
We also assessed whether MRK-003 altered the distribution of the various progenitor cells that have been identified in the mouse mammary epithelium (Smalley et al., 1998) . Primary mouse mammary epithelial cells form four types of morphologically distinct colonies representing different progenitor cell populations. Type A and D colonies comprise only luminal or myoepithelial cells, respectively, and hence likely arise from unipotent progenitor cells; whereas, type B and C colonies are composed of both luminal and myoepithelial cells, and thus are the progeny of bipotent progenitor cells. We have independently confirmed the cellular composition of the various colony types arising from primary mammary epithelial cells by co-staining the cells with antibodies to a-Sma and Ck8, markers of myoepithelial and luminal lineage cells, respectively (Kurpios et al., 2009) .
We compared the frequency of the various colony types arising from primary mammary epithelial cells in the presence of the vehicle or of MRK-003 (2 mmol/l). MRK-003 increased the frequency of D-type colonies and reduced that of C-type colonies ( Figure 2b ). The morphology of the colonies seeded by primary tumor cells were very similar to each other and was unaffected by MRK-003. To determine whether MRK-003 altered the cellular composition of the tumor cell colonies we co-stained them with antibodies to myoepithelial and luminal lineage markers. The majority (B85%) of the colonies seeded by the vehicle-treated primary tumor cells comprised cells that only expressed the luminal marker ( Figure 2c , top-most panel labeled vehicletreated), whereas the remaining colonies were composed of cells that expressed either the luminal or the myoepithelial cell marker (Figure 2c , bottom-most panel labeled vehicle-treated). The latter results are consistent with the observation that mammary tumors arising in this model primarily comprise cells that express luminal lineage markers (Cardiff, 2003) . When MRK-003 was present during colony formation, the frequency of tumor cell colonies comprising only luminal-lineage cells declined from B85 to B40%, whereas that of the 
MRK-003 targets TIC in vitro
To determine whether MRK-003 targets TIC, we exposed freshly prepared primary tumor cells to the vehicle or to various concentrations of MRK-003 for 4 days, dissociated any spheres that arose, injected B10 000 viable dispersed cells from the spheres subcutaneously into eight syngeneic immune-competent mice, and thereafter monitored tumor formation. When a tumor estimated to constitute 10% of the weight of any individual mouse arose, all the mice in the experiment were killed and the volume of the tumors was determined. We chose to inject the mammary tumor cells subcutaneously because this method can be accomplished much more rapidly and are much less invasive than performing orthotopic cell transplantation. Importantly, we have found that TIC frequency in tumors of the N202 model determined by orthotopic or subcutaneous tumor cell transplantation is the same (Kurpios et al., manuscript submitted). Moreover, the morphology (Supplementary Figure 3) , cellular composition (described in Figure 3 below) and transcript profiles of the primary mammary tumors and those resulting from orthotopic or subcutaneous cell transplantation were essentially identical (Supplementary Table 1 ). Indeed tumors that formed after subcutaneous tumor cell injection were invariably found in the fat pad of the #2 mammary gland, a stromal environment similar to that of mammary tumors in the transgenic strain or those resulting from orthotopic tumor cell transplantation (data not shown).
All eight mice injected with the vehicle-treated tumor cells formed tumors, and whereas these varied in volume, they averaged 240 mm 3 (Figure 3a ). By contrast, mice injected with MRK-003-treated tumor cells formed tumors at lower frequencies and smaller volumes directly proportional to the concentration of MRK- 003 to which they were exposed. No tumors arose from transplant of tumor cells treated with the highest doses of MRK-003 (5.0 mmol/l) used in these experiments.
We were able to recover viable cells from the tumors of mice injected with tumor cells exposed to the lowest concentration (0.125 mmol/l) of MRK-003; subcutaneous injection of B10 000 cells from each of four such tumors did not yield any tumors in syngeneic mice 6 months post-transplantation. By contrast, transplant of the same number of cells isolated from tumors of the vehicle-treated tumor cells led to 1-2 g tumors in three of four recipient mice after 4 months. Hence, exposure of primary tumor cells to MRK-003 in vitro eliminated TIC from these cell populations as assessed by tumor cell transplantation.
Hematoxylin and eosin staining of tumor sections revealed that the morphology of the tumors formed by the MRK-003-treated tumor cells was dramatically different from that seeded by vehicle-treated tumor cells (Figure 3b ). There were many localized cell-free areas or lumens that often contained material in the tumor sections arising from the MRK-003-treated tumor cells. Notably, these cell-free areas appeared to be encircled by a ring of tumor cells. Hence, transient incubation of tumor cells with MRK-003 in vitro for 4 days was manifest many months later in an altered histopathology of tumors arising from transplant of these cells.
We also examined the cellular composition of the subcutaneous tumors. Like mammary tumors occurring in N202 transgenic mice (Cardiff, 2003) , those formed subcutaneously by the vehicle-treated tumor cells comprised predominantly Ck8-positive luminal-like cells (Figure 3c , sections of two independent tumors are shown). There were very few Ck14-or a-Sma-positive myoepithelial lineage cells in these tumors. By contrast, the tumors formed after transplant of the MRK-003- 
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treated tumor cells comprised many myoepithelial lineage-restricted cells, which were frequently organized into duct-like structures that stained brightly with antibodies to Ck14 or a-Sma (Figure 3d , examples of three independent tumors are shown). It is not clear whether these duct-like structures visualized by staining of the myoepithelial-lineage markers are the same as those identified by hematoxylin and eosin staining of the tumor sections. Most of the cells comprising these tumors expressed both Ck8 and Ck14, or Ck8 and a-Sma.
These data suggest that exposure of tumor cells to MRK-003 for a short period in vitro initiated a differentiation program, whose manifestation was evident months later in tumors seeded by these cells, and which may account in part for the loss of TIC in these tumor cell populations.
MRK-003 shrinks and eliminates tumors in mice
To learn whether MRK-003 targets TIC in tumors, syngeneic mice bearing subcutaneous tumors (B1 cm 3 ) were administered the vehicle or MRK-003 for 3 consecutive days followed by a 4-day recovery; this dosing regimen was repeated once (Lewis et al., 2007; Tammam et al., 2009; Efferson et al., 2010) . The tumors in all the vehicle-treated mice (n ¼ 13) increased in volume (average of 225%), whereas those in the MRK-003-treated cohort either shrank (n ¼ 6) or completely regressed (n ¼ 10) during the 2-week dosing period (Figure 4a ). Three mice in the MRK-003 treatment group possessed very small, but palpable tumors, and were included with the 10 mice whose tumors had completely regressed to monitor tumor recurrence. The tumors completely disappeared in the three mice with small palpable tumors during the 2-week period after the last dose of MRK-003 had been administered. Tumors did not recur in any of these 13 mice for up to a year after MRK-003 administration had been discontinued suggesting that MRK-003 effectively eliminated TIC in the tumors of the vast majority of the mice.
To determine the mechanism whereby tumor regression occurred, histological analyses were performed on sections of tumors from vehicle-treated and MRK-003-treated mice, whose tumors partially regressed during the treatment period. As observed previously the morphology of the subcutaneous tumors in the vehicle-treated mice was very similar to that of mammary tumors occurring in the transgenic strain (Figure 4b , top panels) (Cardiff, 2003) . By contrast, tumor sections from mice administered MRK-003 comprised many localized cell-free areas (Figure 4b) , reminiscent of the morphology of tumors seeded by tumor cells that had been exposed to MRK-003 in vitro (Figure 3b) . No histological differences were observed in sections of the mammary glands of the tumor-bearing mice treated with either the vehicle or MRK-003, indicating that the compound did not affect their gross morphology (Figure 4b, bottom panels) .
The occurrence of many cell-free areas in the tumors of MRK-003-treated mice suggested that the compound-induced cell death. To determine whether cell death occurred by apoptosis, we stained sections of these tumors with an antibody specific to active caspase-3 (Figure 4c ). We observed a dramatically increased frequency of active caspase-3-positive cells in the tumors of MRK-003-treated mice (B25%) compared with those administered the vehicle (B1%) (Figure 4c , bar diagram). TdT-mediated dUTP nick end labeling assays confirmed the latter findings (Figure 4c) .
Exposure of tumor cells to MRK-003 in vitro promoted their differentiation toward the myoepithelial lineage. To determine whether MRK-003 had a similar effect in vivo, tumor sections were co-stained with antibodies to luminal (Ck-8) and myoepithelial (a-Sma) markers. The tumors from vehicle-treated mice comprised predominantly Ck8-positive cells (Figure 4d , top panels), whereas those from MRK-003-treated mice contained areas of cells that expressed only a-Sma, or more generally both markers ( Figure 4d , bottom panels; Supplementary Figure 4) . We observed duct-like rings of brightly stained a-Sma-expressing cells in tumors of mice administered MRK-003 similar to those identified in tumors that arose from transplant of tumor cells that had been treated with MRK-003 in vitro (Figure 4d ). These data suggest that MRK-003 altered the fate of the luminal-like, tumor-resident cells resulting in their differentiation towards the myoepithelial lineage.
We also stained tumor sections from vehicle-and MRK-003-treated mice with antibodies to Ki67, a marker of cell proliferation. However, we did not observe any difference in the percentage of Ki-67-positive cells between these samples. As the tumor sections were prepared from mice that had been killed 4 days after the last dose of MRK-003 had been administered, any short-term effect of the gamma (g)-secretase inhibitor on cell proliferation may have been missed. Hence, we treated tumor-bearing mice with the vehicle or a single dose of MRK-003, and prepared tumor sections from these mice 2 days thereafter. The frequency of Ki-67-positive cells was dramatically reduced in the tumor sections of the MRK-003-treated mice compared with those of the vehicle-treated mice (Figures 5a and b) .
To learn whether administration of MRK-003 to tumor-bearing mice affected Notch signaling, we measured the transcript levels of Hey1, a Notch target gene, in their tumors. Mice bearing subcutaneous tumors were administered the vehicle or MRK-003, and 2 days later tumor RNA was isolated and Hey1 RNA abundance determined by quantitative RT-PCR normalized to that of glyceraldehyde 3-phosphate dehydrogenase. Hey1 transcripts were reduced by about sixfold in two independent tumors of mice that were administered MRK-003 compared with tumors from the vehicletreated mice suggesting that MRK-003 attenuated Notch signaling in tumor-resident cells (Figure 5c ). mammosphere-forming cells, but the reversibility of these inhibitors was not addressed in a previous study (Dontu et al., 2004) .
MRK-003 altered the fate of progenitor cells in mammary epithelial cell populations by skewing their differentiation toward the myoepithelial lineage. MRK-003 seemed to specifically affect bipotent progenitor cells that form type C colonies; the frequency of type C colonies was reduced and that of type D colonies, which comprise only myoepithelial cells, was increased by exposing these cells to MRK-003 during colony formation. MRK-003 similarly altered the differentiation of tumor cells, which normally express only luminallineage markers. Recent findings reveal that luminal progenitor cells may be the cells of origin of the Neuinduced tumors in the Neu (N202) transgenic strain (Jeselsohn et al., 2010) . The effect of MRK-003 on mammary epithelial progenitor cell and tumor cell differentiation is consistent with an effect on Notch signaling; numerous studies have demonstrated that this pathway commits normal human and mouse mammary epithelial progenitor cells to the luminal fate and suppresses their differentiation toward the myoepithelial lineage (Buono et al., 2006; Bouras et al., 2008; Raouf et al., 2008; Yalcin-Ozuysal et al., 2010) .
MRK-003 caused rapid tumor regression in the vast majority of mice treated with the compound. Using the dosing regimen developed previously (Lewis et al., 2007; Tammam et al., 2009; Efferson et al., 2010) , we observed no weight loss or other obvious manifestations of the compound during the 2-week treatment period. The effect of MRK-003 on tumor regression was durable; none of the mice whose tumors completely regressed experienced recurrences during a 1-year follow-up period. We also did not observe any overt morphological changes in the mammary glands of mice that had been administered MRK-003. Mice whose tumor completely regressed remained healthy for a year following MRK-003 administration before the experiment was terminated, suggesting that the activity of any essential adult stem cells was not compromised during the treatment period.
Conventional breast cancer chemotherapies initially inhibit tumor re-growth but patients frequently relapse years after treatment. One explanation for these findings is that breast tumors comprise a population of chemoresistant TIC. Indeed recent studies of patient tumors before and after therapy support the contention that breast TIC are chemo-resistant and underscore the need to develop therapies that target these cells (Chang et al., 2005; Li et al., 2008; Creighton et al., 2009) . Our findings illustrate that MRK-003 targets breast TIC as well as non-tumorigenic tumor cells without any deleterious consequences for adult stem cells and thus provides proof-of-principle that eliminating these cells can afford long-lasting cancer cures.
Materials and methods
Mice
All procedures involving mice were performed with the approval of the Canadian Council on Animal Care.
Establishment and propagation of mammary epithelial cells and tumor cells in vitro
We previously reported the methods to process mouse mammary glands and tumors to obtain dispersed primary cells (Shepherd et al., 2001; Kurpios et al., 2009 ). Mammospheres or tumorspheres were established by plating primary cells in stem cell medium (Reynolds and Weiss, 1992) , which comprises Dulbecco's modified Eagle's medium:Ham's F-12 (3:1), 4 mg/ml of B-27, 20 ng/ml EGF, 40 ng/ml FGF-2 and 4 ng/ml Heparin (all from Invitrogen, Carlsbad, CA, USA) (Youn et al., 2005 (Youn et al., , 2006 Kurpios et al., 2009) . Spheres arising from primary cells were passaged every 4 days by mechanical dissociation followed by plating the dispersed cells at a density of B30 000 cells per ml in stem cell medium. Tumorspheres and mammospheres that had been serially passaged between two and five times were used for the experiments reported herein.
Sphere-and colony-forming assays The frequency of sphere-forming cells in primary mammary epithelial cell populations was determined by seeding B100 000 cells in 1 ml of stem cell medium in triplicate into the wells of a 24-well flat-bottom plate and then counting the number of spheres (480 mm) that arose a week later. The frequency of sphere-forming cells in primary tumor cell populations, and established mammosphere and tumorsphere populations was determined by plating B5000 cells in 0.2 ml of stem cell medium in triplicate into wells of a 96-well plate as described above. The frequency of sphere-forming cells in cell populations was calculated by dividing the number of spheres that arose by the number of cells that were seeded multiplied by 100. The frequency of the sphere-forming cells in the MRK-003-exposed cell samples was normalized to that of the corresponding control cell samples exposed to the vehicle (0.1% dimethylsulphoxide) to establish their relative sphereforming frequency. Colony-forming assays were performed as we described previously (Kurpios et al., 2009) . Cells incubated with the vehicle (0.1% dimethylsulphoxide) also served as the controls in the colony-forming assays that employed MRK-003. Sphere-and colony-forming assays were performed with three individual preparations of primary mammary epithelial cells and primary tumor cells (from three independent tumors), as well as with three independent cultures of established mammospheres and tumorspheres.
RNA isolation and analyses
Total RNA was isolated (Trizol Reagent; Invitrogen) from three populations of mammospheres and tumorspheres that originated from different mice and independent tumors. Quantitative RT-PCR was performed on each RNA sample using primer pairs specific for transcripts encoding Notch pathway components and target genes arrayed in 96-well plates as recommended by the manufacturer (RT 2 Profiler PCR Array; SABiosciences, Fredrick, MD, USA). Hey-1 transcript abundance was determined by quantitative RT-PCR using tumor RNA samples from a vehicle-and two MRK-003-treated mice. The tumors were resected from mice 48 h after they had been administered a single dose of MRK-003. Reverse transcription was performed utilizing Superscript II First-Strand Synthesis System for RT-PCR (Invitrogen). The resulting complementary DNA was amplified with the primers complimentary to mouse Hey1 transcript (sequences available on request) using a LightCycler DNA amplification kit SYBR Green I, and a Light Cycler Instrument (Roche, Indianapolis, IN, USA). Primers for the housekeeping gene GAPDH (glyceraldehyde 3-phosphate dehydrogenase) were used as a reference. Results were analyzed using Light Cycler Software 4 (Roche).
Histology, immunofluorescence and immunohistochemical analyses Tumors were fixed in 4% paraformaldehyde, embedded in paraffin and sectioned at 5 mm (Shepherd et al., 2001; Kurpios et al., 2009) . Tumor sections were stained with hematoxylin and eosin solution to reveal their histology. We previously reported the conditions to identify proliferating and apoptotic cells, and those to assess the expression of mammary lineagespecific markers in cell colonies or tumor sections (Kurpios et al., 2009) . Slides of tumor sections or cell colonies were prepared with mounting media containing 4 0 ,6 0 -diamindino-2-phenylindole (Vector Laboratories, Burlingame, CA, USA) to visualize nuclei.
Tumorigenesis studies
Primary tumor cells were suspended in a 1:1 mixture of phosphate-buffered saline containing 5% fetal bovine serum and Matrigel (BD Biosciences, Bedford, MA, USA), and injected subcutaneously between the shoulders of 6-to 8-weekold female FVB/N mice. The occurrence of palpable tumors was monitored weekly. Mice bearing tumors (B1 cm 3 ) were administered the vehicle (0.5% methylcellulose) or 150 mg/kg of MRK-003 freshly dissolved in the vehicle by oral gavage for 3 consecutive days followed by a 4-day rest period (Lewis et al., 2007; Tammam et al., 2009; Efferson et al., 2010) . The dosing cycle was repeated once. Tumor volumes were measured twice a week. At the end of the treatment period, 4 days after the last dose of MRK-003, mice were killed, and any residual tumor tissue was removed, weighed and processed for analyses. Mice whose tumors had completely or nearly completely regressed were monitored for tumor recurrence for 1 year. MRK-003 was a kind gift from Merck, Inc (Boston, MA, USA).
Data analysis
Bar diagrams in the figures show the mean ± s.d. of a minimum of three biological experiments; three technical replicates were performed within each biological experiment. The KruskalWallis test was performed followed by Dunn's multiple comparison test and the unpaired t-test with Welch's correction for unequal variances were performed to analyze the data for the tumorigenesis studies. Differences were considered statistically significant if Po0.05.
